TSCAN THERAPEUTICS IN

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

01 Jun 2023 16:10:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Closing of Public Offering

01 Jun 2023 16:05:35 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Pricing of $140 Million Public Offering

26 May 2023 00:37:03 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Launch of Proposed Public Offering

25 May 2023 16:06:50 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

24 May 2023 16:13:47 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

17 May 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

10 May 2023 07:00:01 By Nasdaq GlobeNewswire

Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

09 May 2023 09:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting

02 May 2023 16:42:10 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

10 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces CEO Transition

31 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies

14 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the Barclays Global Healthcare Conference

13 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

08 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

21 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

23 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022

12 Dec 2022 07:00:00 By Nasdaq GlobeNewswire